efpeglenatide
Selected indexed studies
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. (N Engl J Med, 2021) [PMID:34215025]
- Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis. (J Diabetes Metab Disord, 2024) [PMID:38932865]
- Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. (Cureus, 2023) [PMID:37885518]
_Worker-drafted node — pending editorial review._
Connections
efpeglenatide is a side effect of
Sources
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. (2021) pubmed
- Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis. (2024) pubmed
- Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. (2023) pubmed
- Effects of GLP-1 receptor agonists on neurological complications of diabetes. (2023) pubmed
- Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta-analysis of randomized controlled trials. (2022) pubmed
- Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review. (2025) pubmed
- Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. (2022) pubmed
- Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. (2021) pubmed
- Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. (2021) pubmed
- Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. (2021) pubmed